Company Encyclopedia
View More
name
MIRXES-B
02629.HK
Mirxes Holding Company Limited, a micro ribonucleic acid technology company, provides diagnostic solutions for the screening of cancer, cardiovascular, metabolic, and infectious diseases accessible across Singapore and China. The company offers GASTROClear, a blood-based miRNA detection panel consisting of 12 miRNA biomarkers for gastric cancer screening; LUNGClear, a lung cancer screening product candidate; and Fortitude COVID-19 RT-qPCR test kits. It also researches, develops, and manufactures biotechnology, life, and medical science related products. The company was founded in 2014 and is headquartered in Singapore.
1.269 T
02629.HKMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    MIRXES partners with XTALPI to build an integrated diagnosis and treatment platform

    MIRXES-B signed a memorandum of understanding with XTALPI to integrate genomics technology and AI drug discovery platforms, aiming to establish an AI-enabled integrated diagnosis and treatment platform for high-incidence cancers in Asia, particularly gastrointestinal cancers, and to develop early diagnosis and treatment solutions

    AASTOCKS·
    HK
    02629
    -1.96%
    HK
    02228
    -2.32%
    AASTOCKS·
    HK
    02629
    -1.96%
    HK
    02228
    -2.32%

    Mirxes Holding Enters MoU With Xtalpi Holdings

    MiRXES Holding Co Ltd :ENTERS MOU WITH XTALPI HOLDINGSCO AND XTALPI TO BUILD AI PLATFORM FOR ASIAN HIGH-INCIDENCE CANCERS, OTHERS

    Reuters·
    HK
    02629
    -1.96%
    HK
    02228
    -2.32%
    Reuters·
    HK
    02629
    -1.96%
    HK
    02228
    -2.32%

    Mirxes Holding Co. Ltd. Signs MOU with XtalPi for AI-Driven Cancer Diagnosis and Intervention Platform

    Mirxes Holding Co. Ltd. has signed an MOU with XtalPi Holdings Limited to develop an AI-driven platform for early cancer diagnosis and intervention, focusing on gastrointestinal cancers in Asia. This collaboration aims to integrate Mirxes' genomics technology with XtalPi's AI drug discovery platform, enhancing R&D capabilities and supporting Mirxes' growth and revenue diversification. The partnership's continuation is not guaranteed.

    Reuters·
    HK
    02629
    -1.96%
    HK
    02228
    -2.32%
    Reuters·
    HK
    02629
    -1.96%
    HK
    02228
    -2.32%

    19,286,400 Ordinary Shares of Mirxes Holding Company Limited are subject to a Lock-Up Agreement Ending on 23-NOV-2025.

    19,286,400 Ordinary Shares of Mirxes Holding Company Limited are subject to a Lock-Up Agreement ending on 23-NOV-2025. These shares will be under lockup for 185 days starting from 22-MAY-2025. Cornerstone Investors and co-founders are restricted from disposing of shares during the lock-up period and nine-month period respectively, without prior written consent from the Company and Joint Sponsors.

    marketscreener·
    HK
    02629
    -1.96%
    marketscreener·
    HK
    02629
    -1.96%

    Mirxes Holding Signs Strategic RNA Medicine Partnership with Walvax

    Mirxes Holding Co. Ltd. has signed an MOU with Walvax Biotechnology Co., Ltd. for a two-year strategic partnership. The collaboration aims to develop an RNA-centric preventive and precision medicine platform, focusing on joint development, clinical trials, registration, sales, and distribution of medical solutions. The goal is to advance early detection and preventive medicine. However, the collaboration under the MOU may or may not proceed.

    Reuters·
    SZ
    300142
    -0.62%
    HK
    02629
    -1.96%
    Reuters·
    SZ
    300142
    -0.62%
    HK
    02629
    -1.96%
    © 2025 Longbridge｜Disclaimer